RECARBRIO

Peak

imipenem anhydrous, cilastatin, and relebactam anhydrous

NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

Dipeptidase Inhibitors

Pharmacologic Class:

Renal Dehydropeptidase Inhibitor

Loss of Exclusivity

LOE Date
Mar 21, 2033
85 months away
Patent Expiry
Mar 21, 2033
Exclusivity Expiry
Jul 16, 2029

Patent Records (1)

Patent #ExpiryTypeUse Code
8487093
Mar 21, 2033
SubstanceProduct
U-2586